Emergent Biosolutions, Inc. (EBS) Shares Bought by Macquarie Group Ltd.

Macquarie Group Ltd. increased its stake in shares of Emergent Biosolutions, Inc. (NYSE:EBS) by 60.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,573 shares of the biopharmaceutical company’s stock after acquiring an additional 15,604 shares during the period. Macquarie Group Ltd. owned about 0.10% of Emergent Biosolutions worth $1,681,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Dimensional Fund Advisors LP increased its stake in Emergent Biosolutions by 7.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock valued at $74,795,000 after buying an additional 152,029 shares during the last quarter. Aberdeen Asset Management PLC UK increased its stake in Emergent Biosolutions by 7.3% in the 2nd quarter. Aberdeen Asset Management PLC UK now owns 1,737,470 shares of the biopharmaceutical company’s stock valued at $58,918,000 after buying an additional 118,894 shares during the last quarter. Royal Bank of Canada increased its stake in Emergent Biosolutions by 2.1% in the 2nd quarter. Royal Bank of Canada now owns 958,568 shares of the biopharmaceutical company’s stock valued at $32,505,000 after buying an additional 19,833 shares during the last quarter. Northern Trust Corp increased its stake in Emergent Biosolutions by 47.2% in the 2nd quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock valued at $30,747,000 after buying an additional 290,863 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Emergent Biosolutions by 16.7% in the 2nd quarter. Renaissance Technologies LLC now owns 820,411 shares of the biopharmaceutical company’s stock valued at $27,820,000 after buying an additional 117,700 shares during the last quarter. Hedge funds and other institutional investors own 92.70% of the company’s stock.

Several equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $43.00 price target (up from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $46.00.

Emergent Biosolutions, Inc. (NYSE EBS) traded down $0.20 during trading on Thursday, hitting $42.16. 235,500 shares of the stock traded hands, compared to its average volume of 344,524. The firm has a market cap of $1,753.51, a price-to-earnings ratio of 22.41, a PEG ratio of 1.17 and a beta of 1.24. Emergent Biosolutions, Inc. has a one year low of $26.16 and a one year high of $44.97. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.32. The company had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. Emergent Biosolutions’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.56 EPS. sell-side analysts anticipate that Emergent Biosolutions, Inc. will post 1.64 earnings per share for the current fiscal year.

In related news, EVP Adam Havey sold 7,885 shares of Emergent Biosolutions stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $37.06, for a total transaction of $292,218.10. Following the completion of the sale, the executive vice president now owns 33,931 shares of the company’s stock, valued at approximately $1,257,482.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronald Richard sold 1,266 shares of Emergent Biosolutions stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $40.00, for a total transaction of $50,640.00. Following the sale, the director now directly owns 24,676 shares of the company’s stock, valued at approximately $987,040. The disclosure for this sale can be found here. Insiders have sold a total of 263,193 shares of company stock worth $10,671,852 over the last 90 days. 16.50% of the stock is owned by company insiders.

WARNING: This report was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/07/emergent-biosolutions-inc-ebs-shares-bought-by-macquarie-group-ltd.html.

Emergent Biosolutions Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply